Natera (NASDAQ:NTRA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Natera (NASDAQ:NTRA – Get Rating) in a report published on Thursday morning. The firm issued a sell rating on the medical research company’s stock.

NTRA has been the subject of several other reports. Credit Suisse Group lifted their price objective on Natera from $55.00 to $65.00 and gave the stock an outperform rating in a report on Wednesday, March 1st. Stephens reduced their price objective on Natera to $67.00 in a report on Wednesday, November 16th. Raymond James lifted their price objective on Natera from $58.00 to $68.00 and gave the stock an outperform rating in a report on Friday, March 3rd. Piper Sandler lifted their price objective on Natera from $70.00 to $80.00 in a report on Friday, February 17th. Finally, Morgan Stanley lifted their price objective on Natera from $70.00 to $72.00 and gave the stock an overweight rating in a report on Thursday, March 2nd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $79.27.

Natera Stock Down 2.8 %

Natera stock opened at $56.63 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.90 and a quick ratio of 3.79. Natera has a 1-year low of $27.35 and a 1-year high of $59.75. The company has a market cap of $6.42 billion, a PE ratio of -10.17 and a beta of 1.20. The stock’s 50 day moving average price is $47.11 and its 200 day moving average price is $44.26.

Natera (NASDAQ:NTRA – Get Rating) last posted its quarterly earnings results on Tuesday, February 28th. The medical research company reported ($1.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.03. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. The firm had revenue of $217.30 million for the quarter, compared to the consensus estimate of $215.50 million. During the same period in the previous year, the business earned ($1.48) earnings per share. The company’s revenue for the quarter was up 25.6% compared to the same quarter last year. On average, sell-side analysts predict that Natera will post -4.22 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 9,312 shares of the business’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $55.96, for a total value of $521,099.52. Following the completion of the transaction, the insider now directly owns 175,387 shares of the company’s stock, valued at $9,814,656.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Daniel Rabinowitz sold 9,312 shares of the business’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $55.96, for a total value of $521,099.52. Following the completion of the transaction, the insider now directly owns 175,387 shares of the company’s stock, valued at $9,814,656.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 48,697 shares of Natera stock in a transaction on Monday, January 30th. The shares were sold at an average price of $42.08, for a total value of $2,049,169.76. Following the completion of the sale, the chief financial officer now directly owns 103,990 shares of the company’s stock, valued at approximately $4,375,899.20. The disclosure for this sale can be found here. Insiders sold a total of 187,145 shares of company stock valued at $8,648,357 over the last three months. 10.27% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ronald Blue Trust Inc. purchased a new stake in shares of Natera in the second quarter valued at $26,000. Belpointe Asset Management LLC purchased a new stake in shares of Natera in the fourth quarter valued at $28,000. Quadrant Capital Group LLC grew its position in shares of Natera by 4,595.2% in the second quarter. Quadrant Capital Group LLC now owns 986 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 965 shares during the period. OLD Mission Capital LLC purchased a new stake in shares of Natera in the fourth quarter valued at $36,000. Finally, First Horizon Advisors Inc. grew its position in shares of Natera by 970.2% in the third quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 912 shares during the period. Hedge funds and other institutional investors own 93.81% of the company’s stock.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).